Buy Definium Ahead of September Catalyst — High Reward If DT120 Readout Confirms Two-Indication Signal
Definium Therapeutics has the makings of a classic biotech asymmetric trade: a mid-cap market cap of roughly $5.7B, low leverage, heavy short interest, and an upcoming September 2026 catalyst tied to its CNS program. If the market validates the reported positive DT120 oral disintegrating tablet (ODT) data across two indications, upside to the mid-$…